Skip to content

SENSE (Subcutaneous and Epidural Neuromodulation System Evaluation) Study

TerminatedNot applicableNCT01990287
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

The purpose of the study is to demonstrate safety and efficacy of spinal cord stimulation with peripheral nerve field stimulation for the treatment of chronic low back and leg pain.

Study details

Official title
SENSE (Subcutaneous and Epidural Neuromodulation System Evaluation)Study for the Treatment of Chronic Low Back and Leg Pain
Conditions
Interventions
  • Device: SCS and PNfS
  • Device: SCS Alone
Sponsor
Abbott Medical Devices
Start date
2013-11
Primary completion
2016-02
Sex
All
Age range
from 22 Years
Results posted
No results posted in this snapshot
Countries
United States
Total sites listed
28

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Key Inclusion Criteria: * Subject is 22 years of age or older * Subject has chronic low back and leg pain secondary to Failed Back Surgery Syndrome (FBSS) * Subject has an average score of 6 or higher for average daily overall pain on the Numerical Rating Scale (NRS) based on the 7 day pain diary * Subject has attempted "best" medical therapy and has tried and failed at least three documented medically supervised treatments (including, but not limited to physical therapy, acupuncture, etc.) and has failed medication treatment from at least two different classes * Subject's pain-related medication regimen is stable 4 weeks prior to the baseline evaluation * Subject agrees not to add or increase pain-related medication throughout the 12 week randomized evaluation phase of the study (starting at activation) Key Exclusion Criteria: * Subject currently participating in a clinical investigation that includes an active treatment arm * Subject has been implanted with a previous neuromodulation system (PNfS, SCS-PNfS or SCS) or participated in a trial for a neuromodulation system * Subject's overall Beck Depression Inventory II Score is \> 24 or has a score of 3 on question 9 relating to suicidal thoughts or wishes at the baseline visit * Subject with an infusion pump or any implantable neurostimulator device * Subject has an existing medical condition that is likely to require repetitive MRI evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor) * Subject has an existing medical condition that is likely to require the use of diathermy in the future * Subject has peripheral vascular disease * Subject is immunocompromised * Subject has documented history of allergic response to titanium or silicone * Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection * Female candidates of child bearing potential that are pregnant (confirmed by positive pregnancy test)

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01990287